Search the Newsreel

Ardelyx Inc (ARDX) News, Articles, Events & Latest Updates

This article compiles recent news and updates concerning Ardelyx Inc (ARDX), highlighting its stock performance, recent financial reports, analyst ratings, and significant events. It covers topics like earnings expectations, a Medicare reimbursement battle, insider transactions, and commentary on the company's path to profitability. The …

How Investors Are Reacting To Ardelyx (ARDX) Rising Revenues Amid Growing Analyst Earnings Caution

Ardelyx (ARDX) is experiencing rising quarterly revenues and a smaller loss per share, yet analysts are becoming more cautious, cutting earnings estimates. This creates a tension between the company's operational progress and analyst confidence in near-term earnings. The article discusses how this might influence …

Ardelyx (ARDX) to Announce Earnings on Thursday

Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know

New Strong Sell Stocks for July 29th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ardelyx ARDX is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised almost 14.3% downward over the last 60 days. Banco Do Brasil …

Ardelyx Number of Employees 2026 | Employee Count & Headcount Data

Ardelyx, Inc. (NASDAQ: ARDX) had approximately 508 employees worldwide as of March 2026, representing a 139.4% growth from 212 employees in 2023. The company is actively hiring, with 127 active job postings in 2026, an 85.4% increase from 2025. Ardelyx is headquartered in Waltham, …

Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Ardelyx Inc (ARDX), detailing its price momentum, support and resistance levels, and various technical indicators. It notes that ARDX ranks 373 out of 385 in the Biotechnology & Medical Research industry for price momentum and is currently …

Ardelyx Inc (ARDX) Institutional Confidence

Ardelyx Inc (ARDX) has a current institutional shareholding score of 7.00, placing it 80th out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 71.25%, which is a quarter-over-quarter decrease of 7.13%. Steven Cohen is the largest institutional …

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

Faruqi & Faruqi, LLP is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) following a federal securities class action lawsuit. Investors who suffered losses exceeding $100,000 between October 31, 2023, and July 1, 2024, are encouraged to contact the firm. The lawsuit alleges that …

Ardelyx Inc (ARDX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Ardelyx Inc (ARDX), identifying its major institutional investors and their proportional holdings. It also provides a breakdown of shareholder types and traces institutional shareholding over recent quarters, highlighting changes in shares held and proportions. Additionally, the report …

ARDX|Ardelyx Inc|Price:5.030|Chg%:-0.100

This article provides a detailed financial overview of Ardelyx Inc. (ARDX), including its latest earnings, revenue, EPS, and analyst ratings. It presents a comprehensive data dashboard with quarterly and annual breakdowns of the company's income statement, balance sheet, and cash flow statement, designed for …

Ardelyx (ARDX) Faces A Valuation Test, Is The Discount Too Wide?

Ardelyx (ARDX) is currently trading at a significant discount to analyst targets and intrinsic value estimates, with a fair value estimate of $16.33 against its current share price of $5.03. This undervaluation is supported by the growing prevalence of chronic kidney disease and gastrointestinal …

Ardelyx Inc (ARDX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a dividend and stock split report for Ardelyx Inc (ARDX), indicating that the company has not distributed any dividends over the past five years. It also shows current stock information, including its price, market cap, and P/E TTM. The report states …

TradingKey

This article provides a detailed quarterly and annual balance sheet for Ardelyx Inc (ARDX), displaying financial health metrics such as cash, assets, liabilities, and shareholders' equity over several fiscal years. It also includes frequently asked questions about balance sheet analysis for ARDX stock, clarifying …

Ardelyx Inc (ARDX) Financial Health: Profitability & Balance Sheet Analysis

Ardelyx Inc (ARDX) has a current financial score of 7.75, ranking it 87th out of 386 in the Biotechnology & Medical Research industry, indicating weak financial status but high operating efficiency. The company reported a 27.47% year-over-year increase in its latest quarterly revenue to …

Ardelyx Inc (ARDX) Q4 2025 Earnings Report - Results, Call & Slides

Ardelyx Inc (ARDX) announced its Q4 2025 earnings, reporting actual EPS of $0.00, missing the consensus of $0.23, and comparing to $0.35 a year ago. However, the company beat revenue expectations with $2.19 billion against an expected $2.07 billion, marking a 7.82% year-over-year growth. …

Ardelyx, Inc. Revenue Breakdown – NASDAQ:ARDX

Ardelyx, Inc. (NASDAQ: ARDX) generated $407.32 million in revenue last year, primarily from its Biopharmaceutical Products segment. This represents an increase from $333.62 million in the previous year. The United States was the largest contributor to revenue, accounting for $377.81 million last year.

Ardelyx, Inc. (ARDX) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Ardelyx, Inc. (ARDX) stock, including its current price, historical performance, key financial data, analyst ratings, and company profile. As of 1:15:59 p.m. EDT, ARDX was trading at $5.06, down 1.46%, with a market capitalization of …

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

Ardelyx, Inc. (Nasdaq: ARDX) announced it will report its second quarter 2026 financial results on August 6, 2026. The company will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss these results and provide a business update. Investors can access …

ARDX: Ardelyx Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides current stock information for Ardelyx Inc. (ARDX), including its latest stock price, market capitalization, volume, and upcoming earnings date. It also highlights recent news items related to ARDX, such as a strong sell rating from Zacks and a stock tumble due …

How Investors Are Reacting To Ardelyx (ARDX) Hedge Fund Buying Despite Medicare Setback

Ardelyx is gaining investor attention due to Wall Street's forecast of a shift from losses to profits, driven by strong Ibsrela prescription growth and long-dated patents, despite a setback with Medicare payments for Xphozah. Hedge funds are increasing their positions, indicating institutional confidence in …

Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth Catalysts

Claude AI, via "The Claude Portfolio" account, is bullish on Ardelyx (ARDX), asserting that the market overlooks significant growth catalysts. The AI believes the biotech company is at an inflection point, poised for profitability with its drugs Ibsrela and Xphozah, despite recent stock declines …

Ardelyx (ARDX) Pulls Back As Growth Narrative Raises The Question Of Value

Ardelyx (ARDX) has seen its stock pull back recently, down 10.96% in 30 days and 19.38% in 90 days, despite strong long-term returns. The current debate among investors is whether the stock, closing at $5.20, is undervalued compared to a narrative-driven fair value of …

Ardelyx CEO Michael Raab disposes of 41,668 common shares worth $210,884.22

Ardelyx CEO Michael Raab sold 41,668 shares of common stock on July 15, 2026, at a weighted average price of $5.06, totaling $210,884.22. Concurrently, he exercised stock options for 20,834 shares at an exercise price of $0.99. Following these transactions, his direct holdings in …

Ardelyx CEO Michael Raab sells $210,923 in stock

Ardelyx CEO Michael Raab sold 41,668 shares of company stock for $210,923 on July 15, 2026, while also exercising stock options for 20,834 shares. These transactions were part of a pre-arranged trading plan. The article also mentions the company's Q1 2026 earnings, which resulted …

Ardelyx CEO sells shares, exercises options | ARDX Insider Trading

Ardelyx, Inc. President & CEO Michael Raab reported selling 41,668 common shares at a weighted average price of $5.062 per share and exercising stock options for 20,834 shares at $0.99 per share on July 15, 2026. These transactions were conducted under a Rule 10b5-1 …

Form 4 Ardelyx Inc For: 17 July By Investing.com

This article reports on a Form 4 filing for Ardelyx Inc. on July 17. Form 4 filings are used to report changes in beneficial ownership of company stock by insiders. The article includes the stock symbol ARDX.

Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report

Earnings call transcript: Ardelyx Q1 2026 misses forecasts but shows growth

Ardelyx projects IBSRELA sales to reach $1B a year by 2029